These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 3882312

  • 1. Dopamine reduces aldosterone and 18-hydroxycorticosterone response to angiotensin II in patients with essential low-renin hypertension and idiopathic hyperaldosteronism.
    Witzgall H, Lorenz R, von Werder K, Weber PC.
    Clin Sci (Lond); 1985 Mar; 68(3):291-9. PubMed ID: 3882312
    [Abstract] [Full Text] [Related]

  • 2. Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone.
    Witzgall H, Thayil G, Weber PC.
    Klin Wochenschr; 1982 Aug 16; 60(16):847-52. PubMed ID: 6752560
    [Abstract] [Full Text] [Related]

  • 3. [The role of endogenous dopamine on mineralocorticoids secretion in normal subjects, patients with primary aldosteronism, and idiopathic hyperaldosteronism].
    Shimizu Y.
    Nihon Naibunpi Gakkai Zasshi; 1984 Jan 20; 60(1):1-15. PubMed ID: 6745468
    [Abstract] [Full Text] [Related]

  • 4. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome, and nontumorous hyperaldosteronism.
    Fraser R, Beretta-Piccoli C, Brown JJ, Cumming AM, Lever AF, Mason PA, Morton JJ, Robertson JI.
    Hypertension; 1981 Jan 20; 3(3 Pt 2):I87-92. PubMed ID: 7262982
    [Abstract] [Full Text] [Related]

  • 5. Evidence for endogenous dopaminergic control of mineralocorticoids secretion in normal subjects and in patients with hyperaldosteronism.
    Shimizu Y, Hanew K, Sato S, Sasaki A, Murakami O, Yoshinaga K.
    Tohoku J Exp Med; 1984 Sep 20; 144(1):33-42. PubMed ID: 6506061
    [Abstract] [Full Text] [Related]

  • 6. Effects of corticotropin-releasing factor (CRF) on aldosterone and 18-hydroxycorticosterone in essential hypertension and primary aldosteronism.
    Miyamori I, Yasuhara S, Matsubara T, Okamoto S, Ikeda M, Koshida H, Morise T, Takeda Y, Takeda R, Vecsei P.
    Endocrinol Jpn; 1987 Dec 20; 34(6):809-19. PubMed ID: 2836182
    [Abstract] [Full Text] [Related]

  • 7. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
    Witzgall H, von Werder K, Weber PC.
    J Steroid Biochem; 1983 Nov 20; 19(5):1671-6. PubMed ID: 6645503
    [Abstract] [Full Text] [Related]

  • 8. Altered responses of plasma 18-hydroxycorticosterone and aldosterone to angiotensin II and adrenocorticotropin in patients with a 18-hydroxycorticosterone-producing tumor.
    Uchida K, Kigoshi T, Iwasaki R, Morimoto S.
    Jpn J Med; 1989 Nov 20; 28(4):446-51. PubMed ID: 2554039
    [Abstract] [Full Text] [Related]

  • 9. Dopaminergic regulation of 18-hydroxycorticosterone and aldosterone secretion in man.
    Sowers JR, Beck FW.
    Acta Endocrinol (Copenh); 1983 Feb 20; 102(2):258-64. PubMed ID: 6338674
    [Abstract] [Full Text] [Related]

  • 10. Effect of metoclopramide and domperidone on aldosterone, 18-hydroxycorticosterone and prolactin secretion in the rhesus monkey.
    Sowers JR, Eggena P, Phillips D.
    Metabolism; 1982 Dec 20; 31(12):1219-23. PubMed ID: 7144566
    [Abstract] [Full Text] [Related]

  • 11. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism.
    Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C.
    Clin Sci (Lond); 1981 Dec 20; 61 Suppl 7():289s-293s. PubMed ID: 7032817
    [Abstract] [Full Text] [Related]

  • 12. Adrenal steroid responses to ACTH in glucocorticoid-suppressible aldosteronism.
    Ganguly A, Weinberger MH, Guthrie GP, Fineberg NS.
    Hypertension; 1984 Dec 20; 6(4):563-7. PubMed ID: 6086520
    [Abstract] [Full Text] [Related]

  • 13. Dopaminergic modulation of aldosterone secretion in the rhesus monkey: evidence that dopamine affects the late pathway of aldosterone biosynthesis by inhibiting the conversion of corticosterone to 18-hydroxycorticosterone.
    Sowers JR, Berg G, Martin VS, Mayes DM.
    Endocrinology; 1982 Apr 20; 110(4):1173-7. PubMed ID: 7060520
    [Abstract] [Full Text] [Related]

  • 14. Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism.
    Mizuno K, Yamazaki M, Ikeda K, Yaginuma K, Hashimoto S, Fukuchi S.
    Jpn Heart J; 1983 Nov 20; 24(6):917-24. PubMed ID: 6323781
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Studies on abnormalities of adrenal steroidogenesis in essential hypertension, primary aldosteronism and renovascular hypertension: responses of plasma steroids to angiotensin III].
    Itoh N.
    Nihon Naibunpi Gakkai Zasshi; 1988 May 20; 64(5):419-38. PubMed ID: 3410145
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
    Carey RM, Thorner MO, Ortt EM.
    J Clin Invest; 1979 Apr 20; 63(4):727-35. PubMed ID: 438333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.